Summary Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations ...

Dublin, March 04, 2024 (GLOBE NEWSWIRE) -- The "Glucagon-like Peptide-1 (GLP-1) Agonists Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ...

DelveInsight's THR-β Agonist Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

GLP-1 receptor agonist market is expected to reach USD 55.70 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031. BURLINGAME, CA, UNITED STATES, January 12, 2025 ...

3. Competitive Intelligence Analysis for Lipodystrophy Syndrome 4. Lipodystrophy Syndrome Market Overview at a Glance 5. Lipodystrophy Syndrome: Disease Background and Overview 6.

Dublin, Feb. 20, 2024 (GLOBE NEWSWIRE) -- The "Opioid Kappa Receptor Agonists Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ...

Sahu concludes: “With many Chinese biosimilar versions of GLP-1 agonists gearing up to enter the market, the GLP-1 agonist therapies may become more affordable than tirzepatide.